Simultaneous increase in multiple proinflammatory cytokines in the aqueous humor in neovascular glaucoma with and without intravitreal bevacizumab injection

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 6, 2015, Pages 3541-3548

  Ohira, Saori ^a   Inoue, Toshihiro ^a   Shobayashi, Kohei ^a   Iwao, Keiichiro ^a   Fukushima, Mikiko ^a   Tanihara, Hidenobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Interleukin; MCP 1; Neovascular glaucoma; VEGF

Indexed keywords

BEVACIZUMAB; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ANIMAL EXPERIMENT; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; CATARACT EXTRACTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNODETECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOVASCULAR GLAUCOMA; NONHUMAN; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RABBIT; VITREOUS BODY; ANIMAL; CASE CONTROL STUDY; CATARACT; DISEASE MODEL; GLAUCOMA, NEOVASCULAR; GLAUCOMA, OPEN-ANGLE; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; CASE-CONTROL STUDIES; CATARACT; CROSS-SECTIONAL STUDIES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GLAUCOMA, NEOVASCULAR; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RABBITS;

EID: 84939781021     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15918     Document Type: Article

References (48)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480-1487.
2. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996; 80:241-245.
3. Sone H, Okuda Y, Kawakami Y, et al. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care. 1996; 19:1306-1307.
4. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998; 105:232-237.
5. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412- 416.
6. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996; 114:964-970.
7. Allen RC, Bellows AR, Hutchinson BT, et al. Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology. 1982;89:1181-1187.
8. Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009;147:912- 918.
9. Kim YG, Hong S, Lee CS, et al. Level of vascular endothelial growth factor in aqueous humor and surgical results of Ahmed glaucoma valve implantation in patients with neovascular glaucoma. J Glaucoma. 2009;18:443-447.
10. Inoue T, Inatani M, Takihara Y, Awai-Kasaoka N, Ogata-Iwao M, Tanihara H. Prognostic risk factors for failure of trabeculectomy with mitomycin C after vitrectomy. Jpn J Ophthalmol. 2012;56:464-469.
11. SooHoo JR, Seibold LK, Kahook MY. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013;28:165-172.
12. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol. 2009;19:435-441.
13. Takihara Y, Inatani M, Kawaji T, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma. 2011;20:196-201.
14. Sevim MS, Buttanri IB, Kugu S, Serin D, Sevim S. Effect of intravitreal bevacizumab injection before Ahmed glaucoma valve implantation in neovascular glaucoma. Ophthalmologica. 2013;229:94-100.
15. Mahdy RA, Nada WM, Fawzy KM, Alnashar HY, Almosalamy SM. Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. J Glaucoma. 2013;22:768-772.
16. Yoshida N, Hisatomi T, Ikeda Y, et al. Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens. Graefes Arch Clin Exp Ophthalmol. 2011;249:1547-1552.
17. Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. Arch Ophthalmol. 2010; 128:1539-1545.
18. Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010;248:1601-1609.
19. Chen KH, Wu CC, Roy S, Lee SM, Liu JH. Increased interleukin- 6 in aqueous humor of neovascular glaucoma. Invest Ophthalmol Vis Sci. 1999;40:2627-2632.
20. Min SH, Lee TI, Chung YS, Kim HK. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006;20:162- 165.
21. Yu XB, Sun XH, Dahan E, et al. Increased levels of transforming growth factor-beta1 and -beta2 in the aqueous humor of patients with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2007;38:6-14.
22. Wang ZY, Zhao KK, Zhao PQ. Erythropoietin is increased in aqueous humor of glaucomatous eyes. Curr Eye Res. 2010;35: 680-684.
23. Nassiri N, Nassiri N, Majdi M, et al. Erythropoietin levels in aqueous humor of patients with glaucoma. Mol Vis. 2012;18: 1991-1995.
24. Takihara Y, Inatani M, Seto T, et al. Trabeculectomy with mitomycin for open-angle glaucoma in phakic vs pseudophakic eyes after phacoemulsification. Arch Ophthalmol. 2011;129:152-157.
25. Awai-Kasaoka N, Inoue T, Takihara Y, et al. Impact of phacoemulsification on failure of trabeculectomy with mitomycin- C. J Cataract Refract Surg. 2012;38:419-424.
26. Ogata-Iwao M, Inatani M, Takihara Y, Inoue T, Iwao K, Tanihara H. A prospective comparison between trabeculectomy with mitomycin C and phacotrabeculectomy with mitomycin C. Acta Ophthalmol. 2013;91:e500-e501.
27. Takihara Y, Inatani M, Ogata-Iwao M, et al. Trabeculectomy for open-angle glaucoma in phakic eyes vs in pseudophakic eyes after phacoemulsification: a prospective clinical cohort study. JAMA Ophthalmol. 2014;132:69-76.
28. Inoue T, Kawaji T, Inatani M, Kameda T, Yoshimura N, Tanihara H. Simultaneous increases in multiple proinflammatory cytokines in the aqueous humor in pseudophakic glaucomatous eyes. J Cataract Refract Surg. 2012;38:1389-1397.
29. Kawai M, Inoue T, Inatani M, et al. Elevated levels of monocyte chemoattractant protein-1 in the aqueous humor after phacoemulsification. Invest Ophthalmol Vis Sci. 2012;53: 7951-7960.
30. Inoue T, Kawaji T, Tanihara H. Monocyte chemotactic protein- 1 level in the aqueous humour as a prognostic factor for the outcome of trabeculectomy. Clin Exp Ophthalmol. 2014;42: 334-341.
31. Tripathi RC, Li J, Chan WFA, et al. Aqueous humor in glaucomatous eyes contains an increased level of TGF-β-2. Exp Eye Res. 1994;59:723-727.
32. Welge-Lüßen U, May CA, Neubauer AS, et al. Role of tissue growth factors in aqueous humor homeostasis. Curr Opin Ophthalmol. 2000;12:94-99.
33. Hu DN, Ritch R. Hepatocyte growth factor is increased in the aqueous humor of glaucomatous eyes. J Glaucoma. 2001;10: 152-157.
34. Takihara Y, Inatani M, Kawaji T, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma. 2011;20:196-201.
35. Miller H, Miller B, Zonis S, Nir I. Diabetic neovascularization: permeability and ultrastructure. Invest Ophthalmol Vis Sci. 1984;25:1338-1342.
36. Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol. 2014;132:1350-1354.
37. Hou XR, Miao H, Tao Y, Li XX, Wong IY. Expression of cytokines on the iris of patients with neovascular glaucoma. Acta Ophthalmol. 2015;93:e100-e104.
38. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med (Berl). 1995; 73:333-336.
39. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009;93:273-274.
40. Sasamoto Y, Oshima Y, Miki A, et al. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study. J Ocul Pharmacol Ther. 2012;28:41-48.
41. Zhou M, Chen S, Wang W, et al. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2013;54: 3874-3879.
42. Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2009; 53:243-248.
43. Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci. 2010;51:2388-2392.
44. Jeon S, Lee WK. Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1 day after injection in patients with proliferative diabetic retinopathy. Cytokine. 2012;60: 535-539.
45. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008;14:6371-6375.
46. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932-936.
47. Jung SH, Kim KA, Sohn SW, Yang SJ. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2014;55:2290-2296.
48. Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19:1734-1746.